Mount Sinai Ovarian Cancer Risk Assessment Program

The Mount Sinai Ovarian Cancer Risk Assessment Program provides focused, high quality, innovative care and services for asymptomatic women at increased risk of developing ovarian cancer. The hallmark of the Program is the coordinated, multidisciplinary services provided during each comprehensive visit. These clinical services include evaluations by board certified specialists in cancer genetics, gynecologic oncology, ultrasound, and psychology. The Program is state-of-the-art, combining clinical expertise with our NCI-funded cancer research efforts.

The purpose of the Mount Sinai Ovarian Cancer Risk Assessment Program is to identify and optimize care for those women who are at increased risk for developing ovarian cancer and to develop new tests to detect ovarian cancer at an early, treatable stage.

Multidisciplinary Team Working Toward Accurate Detection

While all cancer patients can potentially benefit from early detection of early stage disease, the development of effective screening methods for epithelial ovarian cancer (EOC) has yet to be accomplished. The Mount Sinai Ovarian Cancer Risk Assessment Program is a collaboration between a team of board certified gynecologic oncologists, led by David A. Fishman, MD, includes Drs. Peter Dottino, Rudy Segna, Annmarie Beddoe, and Linus Chuang.

This Program is an international clinical and scientific effort to develop methods that accurately identify women at increased risk for ovarian cancer. In collaboration with physicians and scientists at the National Cancer Institute, Food and Drug Administration, and other centers of academic excellence, the Program is committed to developing effective means for the accurate detection of women at risk with the ultimate goal of detecting pre-malignant disease and prevention.

Mount Sinai’s Groundbreaking Ovarian Cancer Research

We and other investigators have identified clinically relevant serum/plasma markers based on the latest understanding of ovarian carcinogenesis, invasion, and metastasis, which are combined with newly developed diagnostic technologies (ovarian Pap test, contrast sonography, genomics, molecular biology, tumor immunology, artificial intelligence) and clinical genetics to achieve this goal. The Mount Sinai Ovarian Cancer Risk Assessment Program represents a world-wide integrated, multidisciplinary collaboration of experts working together to identify women at risk.

Evidence suggests that our enhanced understanding of the process of carcinogenesis and inhibition of metastases will require the development of strategies based on the molecular, genetic, and biochemical events that regulate these processes. We continue to investigate many novel blood protein and molecular markers which have significant roles in the regulation of ovarian metastasis and may serve as markers for disease as well as targets for new therapeutics. Genetic evaluation of specimens obtained using the ovarian Pap test allow for the genetic identification of malignant cells prior to the development of physical change and may allow the detection of premalignant cells or ovarian dysplasia. Similarly, new diagnostic imaging technologies such as our use of contrast sonography appear to be promising in detecting cancer early in otherwise normal appearing ovaries.

Contact Us

Mount Sinai Ovarian Cancer Risk Assessment Program
Tel: 212-241-1111

Know Your Body, Know Your Risk

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease.

Watch Videos

dfishman spotlightDavid Fishman talks about the importance of early detection of Ovarian Cancer. View Now

Why This Broadway Beauty Is Showing Off Her Bald Head

valisia lekae spotlightNot only did Broadway star Valisia LeKae survive ovarian cancer, but she was able to keep her uterus and one ovary, so she can still have children. Learn more